Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.

chemotherapy or endocrine therapy for breast cancer

Clinical Trials Referral Office

Judy C. Boughey, M.D.

Matthew P. Goetz, M.D.

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

This study is being done to collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed. We will use the blood and tissue for future studies. These studies will try to find ways to treat future breast cancer patients.

Because there is cancer left in your body after breast cancer treatment is finished, we think the cancer may be different than other cancers. Tissue from surgery will be used to try to grow that kind of cancer in the lab so we can find out more about it and how to treat it.

Blood samples will be used to look at measurements of biomarkers to see how this cancer is different and seek new ways to identify and treat it.

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

Mayo Clinic

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer	NCT04703244	Breast Cancer Residual	chemotherapy or...	18 Years -	Mayo Clinic
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer	NCT04703244	Breast Cancer Residual	chemotherapy or...	18 Years -	Mayo Clinic

Spots Global Cancer Trial Database for chemotherapy or endocrine therapy for breast cancer